Phase 3 Clinical Trials With Primary Completion Dates in September 2025
This is a list of Phase 3 trials with primary completion dates in September 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ALEC | Alector, Inc. | 2025-09-01 | Phase 3 | NCT04374136 | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) |
| ALMS | Alumis Inc. | 2025-09-01 | Phase 3 | NCT06586112 | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis |
| ALMS | Alumis Inc. | 2025-09-01 | Phase 3 | NCT06588738 | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 |
| APLS | Apellis Pharmaceuticals, Inc. | 2025-09-01 | Phase 3 | NCT04770545 | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD |
| BFRI | Biofrontera Inc. | 2025-09-01 | Phase 3 | NCT05662202 | Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp |
| GOSS | Gossamer Bio, Inc. | 2025-09-01 | Phase 3 | NCT05934526 | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) |
| HLBBF | H. Lundbeck A/S | 2025-09-01 | Phase 3 | NCT05164172 | A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine |
| IONS | Ionis Pharmaceuticals, Inc. | 2025-09-01 | Phase 3 | NCT04849741 | A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) |
| KPTI | Karyopharm Therapeutics Inc. | 2025-09-01 | Phase 3 | NCT04562389 | Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis |
| OGN | Organon & Co. | 2025-09-01 | Phase 3 | NCT06134479 | Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation. |
| ORGO | Organogenesis Holdings Inc. | 2025-09-01 | Phase 3 | NCT06000410 | A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients with Osteoarthritis of the Knee |
| SLS | SELLAS Life Sciences Group, Inc. | 2025-09-01 | Phase 3 | NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 |